|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study highlights the prognostic role of p16 in predicting the recurrence-free probability in patients affected by low-grade urothelial bladder and highlights the fact that this method could be used in everyday urologic clinical practice to better characterize the natural history of urothelial bladder carcinomas.
|
17612565 |
2007 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Archival formalin-fixed high-grade penile intraepithelial neoplasias, differentiated penile intraepithelial neoplasias, and invasive carcinomas from a single pathology institution in a low-incidence area for penile cancer were analyzed for 28 HPV low-risk and HPV high-risk genotypes, p16 overexpression, presence of peritumoral lichen sclerosus, lichen planus, precursor lesions, and monoclonal rearrangement of the T-cell receptor γ locus.
|
21681144 |
2011 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
HPV-16 genome was more frequently detected in p16 positive carcinomas, although the difference was not statistically significant.
|
17036393 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Correlations were found in normal tissue specimens between the expression of TAp73 and DeltaNp73 transcripts and that of p53, p14ARF p16INK4a, but these correlations were lost in carcinomas (PTC or FTC).
|
16290057 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Losses of CDKN2A (9p21) and MLH1 (3p22) and gains of CCND1, EMS1 (both at 11q13), RECQL4 and PTP4A3 (both at 8q24) were the most frequent aberrations in both larynx and pharynx carcinomas.
|
17641416 |
2007 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Marked immunoreactivity (++) for p16INK4A and p14ARF was observed in 5/7 carcinomas, 10/12 CIN3, and 1/10 CIN2 lesions and 0/9 CIN1 lesions.
|
16406113 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fluorescence in situ hybridization detected in 38 % of carcinomas a CDKN2A, in 32 % a TP53 and in 8 % an ATM gene deletion, whereas only one B3 thymoma exhibited a CDKNA deletion, and none of the type A thymomas showed a gene loss.
|
27844328 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
P16INK4a immunostaining seems to be a sensitive and specific marker of vulvar carcinomas positive for oncogenic mucosal HPVs.
|
18192968 |
2008 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HPV genotyping polymerase chain reaction (high-risk subtypes 16, 18, 31, 33, 45, 52, and 58) and immunohistochemical expression of p16 were analyzed by using paraffin-embedded tumor biopsies from 143 anal carcinomas.
|
24821878 |
2014 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18.
|
31492932 |
2020 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To investigate whether this distinction in gene expression had prognostic impact, we studied protein expression in an independent cohort of 55 anal carcinomas not included in the microarray study of two differentially expressed candidate genes, minichromosome maintenance complex component 7 (MCM7) and cyclin-dependent kinase inhibitor 2A (CDKN2A or p16).
|
18349847 |
2008 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The surgical pathology archives of The Johns Hopkins Hospital were searched for all carcinomas arising in the sinonasal tract from 1995 to 2011, and tissue microarrays were constructed. p16 immunohistochemical analysis and DNA in situ hybridization for high-risk types of HPV were performed.
|
23095507 |
2013 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Seven of 9 alterations in p16/CDKN2 and p15/MTS2 were observed in serous (3 of 12), endometrioid (3 of 9) and clear-cell (1 of 4) carcinomas.
|
8980248 |
1996 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Three of the four antibodies produced nuclear immunoreactivity in 7 to 14 of the 16 carcinomas carrying p16 mutations; G175-405 showed only weak reactivity in one case.
|
10937052 |
2000 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The protective effect of p16(INK4a) in oral cavity carcinomas: p16(Ink4A) dampens tumor invasion-integrated analysis of expression and kinomics pathways.
|
25523612 |
2015 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Transcriptional silencing of the p16 gene in association with methylation of its 5'-CpG island was examined by methylation-specific PCR in 18 pancreatic carcinomas.
|
9242437 |
1997 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
HPV-positive tumors had a distinct nonkeratinizing basal cell morphology, they stained diffusely and strongly with p16 antibodies, had higher Ki-67 and lower p53 staining scores as compared with the conventional keratinizing HPV negative carcinomas.
|
14576481 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
9p21 allelic loss was observed in 9 cases, but p16(INK4a) expression in these carcinomas was not reduced.
|
16647956 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas.
|
11289098 |
2001 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eight tumors (including three carcinomas) had many somatic copy number variants (CNVs) with frequent deletion of CDC42 and CDKN2A, amplification of 5q31.2 and protein-altering mutations in TP53 and RB1.
|
24747643 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas.
|
8621247 |
1996 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In order to investigate p16INK4 gene alterations in sporadic ampullary carcinomas, 17 sporadic ampullary carcinomas were examined.
|
9414654 |
1997 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of the p16(INK4a) promoter was more common in intestinal type than in diffuse type gastric carcinomas (p = 0.0023; Fisher's exact test) and was inversely associated with p53 mutations (p = 0.0225; Fisher's exact test).
|
12210063 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings confirmed that p16 overexpression is associated to high-grade precancerous lesions and cervical carcinomas, and further demonstrated that immunohistochemical evaluation of p16 may be a useful biomarker in identifying HR-HPV-infected low-grade lesions.
|
16415792 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Carcinomas with a lobular component were p16 negative in 9 of 11 cases (82%).
|
15619212 |
2004 |